Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health... Show more
Koninklijke Philips N.V. (Royal Philips) reported its third-quarter 2026 results on November 3, 2026, giving investors a fresh look at whether the Dutch health technology company can sustain its turnaround. After years of disruption from the Respironics sleep and respiratory care recall, Philips is working to rebuild credibility through margin expansion, productivity savings, and AI-enabled product innovation. This quarter matters because it tests whether stronger order intake is converting into sales growth, whether profitability gains are durable, and whether legal overhangs are finally being resolved. With the company reiterating its full-year guidance, the results offer a key signal on execution heading into the close of its 2026 fiscal year.
Philips reported comparable sales growth of 3% to €4.39 billion for the third quarter of 2026, supported by mid-single-digit growth in Connected Care and high-single-digit growth in Personal Health. Adjusted EBITA increased to €569 million from €531 million a year earlier, and the adjusted EBITA margin expanded 70 basis points to 13.0%, with expansion across all business segments. Comparable order intake rose 8%, driven by strong momentum in Diagnosis & Treatment, where order growth approached 20%.
On a reported basis, net income dropped to €28 million from €187 million, reflecting a €288 million provision related to an agreement in principle with the U.S. Department of Justice (DOJ) to resolve criminal and civil investigations into the Respironics recall. Adjusted earnings per share came in at €0.40, up from €0.36 a year earlier, and beat analyst consensus. Free cash flow strengthened to €384 million, up from €172 million in the prior-year quarter.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Koninklijke Philips (PHG) or comparing peers across the medical technology space, the AI Screener can provide a structured starting point for further research.
Philips shares climbed following the release, rising roughly 3% to €25.31 in Amsterdam trading and reaching their highest level since early March, while U.S.-listed American depositary receipts (ADRs) traded higher in premarket activity. Investors appeared to focus on the stronger-than-expected adjusted earnings and order intake rather than the one-time legal provision, which was widely anticipated following the DOJ announcement. Analysts described the quarter as mixed, noting that the beat in adjusted EBITA and solid Connected Care performance were offset by sluggish Diagnosis & Treatment sales, where ultrasound shipment phasing and softer China demand weighed on growth. The market's positive response suggests sentiment is rewarding progress on margins and orders, even as questions linger about the pace of revenue acceleration.
Philips reiterated its full-year 2026 guidance, projecting comparable sales growth of 3% to 4.5%, an adjusted EBITA margin of 13.5% to 14.0%, and free cash flow of €1.5 billion to €1.7 billion. The margin outlook includes an approximately 1% benefit from U.S. tariff refunds. Management signaled that ultrasound sales delayed by manufacturing process improvements should come through in the fourth quarter and early 2027, supporting an expected acceleration in Diagnosis & Treatment sales.
Investors should watch several factors in the coming quarters. First, the finalization and payment of the Respironics DOJ settlement, expected in the first quarter of 2027, could affect near-term cash flow, while other ongoing Respironics-related proceedings remain outstanding. Second, China's centralized procurement expansion and subdued consumer sentiment remain a key source of uncertainty for the Diagnosis & Treatment and Personal Health segments. Third, the company's ability to convert its growing order book into revenue, particularly in precision diagnosis and image-guided therapy, will be central to achieving its medium-term targets of mid-single-digit comparable sales growth and a mid-teen adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin by 2028.
Cost inflation, tariff dynamics, and the pace of productivity savings under the company's €1.5 billion three-year program will also shape margin trajectory. As Philips continues to launch AI-enabled platforms, the commercial traction of newer products such as its Spectral CT portfolio and helium-free MR systems will offer further insight into the durability of its growth momentum.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a diversified technology company, engages in providing healthcare, consumer lifestyle and lighting services
Industry MedicalNursingServices